Molecular pathogenesis of multiple myeloma: basic and clinical updates
about
First line vs delayed transplantation in myeloma: Certainties and controversiesA novel phthalimide derivative, TC11, has preclinical effects on high-risk myeloma cells and osteoclastsAdvances in understanding prognosis in myeloma.Direct inhibition of c-Myc-Max heterodimers by celastrol and celastrol-inspired triterpenoids.Genetic interrogation of circulating multiple myeloma cells at single-cell resolution.Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival.MicroRNA: important player in the pathobiology of multiple myelomaEfficient transient transfection of human multiple myeloma cells by electroporation--an appraisal.Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma.Genome-wide pharmacologic unmasking identifies tumor suppressive microRNAs in multiple myeloma.Dexamethasone-induced cell death is restricted to specific molecular subgroups of multiple myeloma.Gamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells.BRAFV600 mutations in solid tumors, other than metastatic melanoma and papillary thyroid cancer, or multiple myeloma: a screening study.Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress.Mechanisms of oncogenic chromosomal translocations.The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.MicroRNA-21 and multiple myeloma: small molecule and big function.Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy.Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells' phenotype and translation initiation.Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells.Genomewide association study on monoclonal gammopathy of unknown significance (MGUS).Multiple myeloma cells alter the senescence phenotype of bone marrow mesenchymal stromal cells under participation of the DLK1-DIO3 genomic region.Epigenetic mechanisms of cell adhesion-mediated drug resistance in multiple myeloma.Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroups.Clinical Pharmacokinetics of Vemurafenib.p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCERModifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma.Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance.Impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib/dexamethasone therapy.Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.The therapeutic potential of cell cycle targeting in multiple myeloma.Bortezomib overcomes the negative prognostic impact of renal impairment in a newly diagnosed elderly patient with multiple myeloma: A case report.The Utilization of Karyotyping, iFISH, and MLPA for the Detection of Recurrence Genetic Aberrations in Multiple MyelomaAbdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry.MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma.The selectivity of Marinopyrrole A to induce apoptosis in MCL1high BCL2low expressing myeloma cells is related to its ability to impair protein translation.HIF-2α-ILK Is Involved in Mesenchymal Stromal Cell Angiogenesis in Multiple Myeloma Under Hypoxic Conditions.A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility.PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).
P2860
Q26745957-4EFB1BA0-1C3E-4D3A-8941-719DA630A72CQ28543087-E7380E94-BA7F-441E-B7C8-C31DD2817E42Q30244061-E79DE631-E07B-48B6-A2D0-24A92DD00E80Q30278518-3968F417-4FE0-4E15-A5F0-2FE35F12EE3CQ33664484-243DB40F-AF3C-491C-A507-D513F0999C60Q33705389-F2DF4F31-810E-49D4-9AE4-08974310DC8FQ33786861-54F57200-F0C7-4016-A44B-45E55C5601D9Q35182314-0C5239B2-3CB4-49D7-B1F9-8EE9592A9F86Q35764582-B9A46960-AD95-41FA-86C8-3E1D33F016A6Q36413501-6045D98E-CE47-4E59-9317-479C8A79B07DQ36413655-3BB1F0AB-B9E8-490B-80C6-EACEA279409BQ37085867-B531EC99-1275-4898-BE1B-9E612D8F2EE4Q37661831-375EB5F7-6D4A-4FBA-BDAB-9020D1240AF3Q37705955-06E282B1-0CAF-4618-895D-E22F1D05EDE2Q38188051-ECC2AD03-1820-4852-B380-BD51A14C30A8Q38192044-801AC29B-31BC-4B5C-8CE9-8F68D4A0A19FQ38224963-3132EA0D-2DDC-446C-B2B2-8E4821644104Q38462720-22B2D315-ACDA-4786-872B-29965D01BAC4Q38609866-A3611DD8-583C-481F-A73D-AD177718D898Q38765278-5EC99FC9-3E0D-4974-83BE-922AE5A59DFAQ38856161-6BBF35C2-6070-4A71-8D18-86EAB3485090Q38885705-7C60E81C-8EC5-43DF-B316-5FF6950BD647Q38895512-ACC343DF-D154-42D5-A633-6B63C44804CAQ38927737-7FE8788C-9D58-4A80-B767-583C4896616CQ39159365-7E034873-F9BA-443A-90FD-35A359622325Q40382947-E8BB1C92-6CE0-47FC-9DA4-E77197EE3B91Q40843669-0BEBF0B4-67B9-46FA-BEB2-277369E4CECFQ41591687-4E927204-1FEB-4D3F-9F6B-FFA34F7C880CQ41701970-BAD001A8-ADBB-4B36-83E2-784A569CB91CQ41964351-76F02554-B0E0-41B2-9DFE-00337C10E53FQ44175092-1BE3F5F1-F8DA-4B80-B603-AB1305453D16Q47203904-F282ECA1-E3E8-43C5-B4E6-4F9F2BB486A6Q49199576-B51588B0-71A3-49B9-BCE2-074365C4DD49Q49428299-FC21CA23-0874-43AF-835A-05C4DC5D08A0Q50441841-CE1B62B1-6FCD-453B-A6B3-606AB625631AQ51334810-D15783C1-86A3-42A3-AD27-D06B85851ECDQ51572205-33607701-D658-461C-8F37-42A2926194BDQ52321084-D68C0EAA-A959-4F95-99BB-7E8E99DB1C38Q52653307-31F4999C-D525-4DD2-9A65-31FCA6BD7EE7Q52971499-91199FA7-D1C5-40B7-B3BD-B214AD6CFF71
P2860
Molecular pathogenesis of multiple myeloma: basic and clinical updates
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@ast
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@en
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@nl
type
label
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@ast
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@en
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@nl
prefLabel
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@ast
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@en
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@nl
P2860
P3181
P1476
Molecular pathogenesis of multiple myeloma: basic and clinical updates
@en
P2093
Marta Chesi
P. Leif Bergsagel
P2860
P2888
P304
P3181
P356
10.1007/S12185-013-1291-2
P407
P577
2013-03-01T00:00:00Z
P5875
P6179
1045084082